Allakos Management

Dr Bebbington is a co-founder of Allakos.

He has more than 25 years experience in the biopharmaceutical industry. He held various scientific and leadership roles at Celltech Ltd, including Head of Mammalian Expression and Team leader in Immunomodulation. During this time, he developed expression systems for recombinant antibodies, including the GS-System™, currently used in the manufacture of several approved antibody products, and conducted research into T-cell activation and chimeric antigen receptors. He was Director of Molecular Immunology at Coulter Pharmaceutical Inc., Senior Director of Research at Corixa Corp. and led a team that transferred to Medarex Inc on the acquisition by Medarex of antibody-drug conjugate technology and assets from Corixa. In 2003, Dr Bebbington was a co-founder of Celscia Therapeutics, a therapeutic antibody development company which merged in 2004 to form KaloBios Pharmaceuticals Inc. At KaloBios he was Vice President of Research, leading a team that developed a novel antibody humanization technology, “Antibody Humaneering™”, outlicensed to multiple partners, and entered 4 antibodies into clinical trials. He co-founded Allakos in 2012.

He has a Bachelor of Arts in Natural Science from the University of Oxford, U.K. and a Master of Arts and Doctor of Philosophy also from the University of Oxford.

Received his training in medicine at The National Autonomous University in Mexico City, and his pediatric and allergy immunology training at the University of Texas Health Science Center and at Baylor College of Medicine, respectively. Dr. Dorenbaum joined the faculty of the University of California in San Francisco where he was responsible for a program devoted to clinical research and the care of women and children with HIV infection. Dr. Dorenbaum subsequently worked at Chiron Corporation where he held positions in several areas of drug development, including biologics, small molecules and vaccines. At BioMarin Pharmaceutical, Inc., he was responsible for the clinical development of Kuvan®, and at Genentech, he was responsible for the respiratory programs in asthma and cystic fibrosis. Dr. Dorenbaum also served as Chief Medical Officer at Lumena Pharmaceutical until its acquisition by Shire. He maintains an active academic position as Clinical Professor of Pediatrics at Stanford University School of Medicine where he treats patients with allergy and immunological issues.

Has over 20 years of experience in the heathcare industry. Prior to joining Allakos, Dr Greenwood was Investment Director for the Roche Venture Fund, where he led investments in 23andMe, Allakos, Biodesy, CytomX (NASDQ: CYMX), DVS (acquired by Fluidigm), Epic Sciences, Horizon Discovery (AIM: HZD), Maculogix, ProActa and Stratos. Prior to his role at the Roche Venture Fund, Dr. Greenwood was the head of GenenFund, Genentech's corporate venture fund, and he also held roles in research and business development at Genentech. Dr. Greenwood holds a Ph.D. in Genetics and Development from Columbia University College of Physicians and Surgeons, where he was a Fulbright Scholar.

Dr Tomasevic is a co-founder of Allakos.

He received a Bachelor of Science degree in Chemistry from the University of Belgrade in Yugoslavia and a Master of Science and Ph.D. in Biochemistry at the same university. He completed postdoctoral training at National Institutes of Health (NIDDK, Genetics and Biochemistry Branch) in Bethesda, Maryland in the laboratory of Dr. Brenda Peculis. During the training, he discovered 2 previously uncharacterized proteins. After that, he joined Cytokinetics leading a team that identified small molecule inhibitors of key players involved in actin dynamics i.e. cell motility. The data have been published in prestigious scientific journals. At Nuvelo, he led a protein biochemistry group that accomplished numerous preclinical studies on protein and antibody therapeutics. He was director of Protein biochemistry at KaloBios and his team supported preclinical and clinical activities for 3 clinical-stage antibodies. During this time, he was a team leader for an antibody program in allergy. He co-founded Allakos in 2012.

Received a Bachelor of Science in Biochemistry from Brown University and a PhD in Biological Chemistry from the Hershey Medical Center of Penn State University. She had a post-doctorate appointment at MIT in the Applied Biological Science and was an Assistant Research Professor at Mt. Sinai Medical Center in New York City studying glycoprotein synthesis. She has more than 25 years experience in the biopharmaceutical industry. She held various scientific and leadership roles at Centocor, Inc, including Executive Director for Regulatory Affairs. While at Centocor, she was responsible for preclinical, clinical and manufacturing strategy and submissions for INDs and Marketing Applications for cardiovascular, immunology, oncology and infectious disease products. She joined Human Genome Sciences, Inc. in 2000 and served as the Senior Vice President of Development and Regulatory Affairs with responsibility for formulation and implementation of global regulatory and drug development strategies. She has secured approval for five first-in-class biologics, initiated INDs for over 50 indications, and submitted over 6 BLAs for products including murine, chimeric and human antibodies; radioconjugates; antibody fragments; and fusion proteins. From 2013 until joining Allakos, she was an independent biopharmaceutical consultant.

Has more than 15 years of leadership experience in clinical operations and drug development. He has successfully led clinical operations teams in planning and advancing drug candidates from pre-clinical through IND and proof of concept, up to Phase 3 life cycle investment stage. Prior to Joining Allakos, he was responsible for the Immunology, Infectious Disease, Neuroscience and Ophthalmology early development clinical operations group at Genentech. Prior to Joining Genentech Omer was a Senior Director in the CNS group at a rapidly growing contract research organization specializing in planning and executing drug development programs for numerous biotech and pharmaceutical clients. Omer received his undergraduate degree in Biology from University of Western Ontario, one of the leading universities in Canada and is pursuing his Masters of Science degree in Biotechnology from Johns Hopkins University.

Dr Bebbington is a co-founder of Allakos.

He has more than 25 years experience in the biopharmaceutical industry. He held various scientific and leadership roles at Celltech Ltd, including Head of Mammalian Expression and Team leader in Immunomodulation. During this time, he developed expression systems for recombinant antibodies, including the GS-System™, currently used in the manufacture of several approved antibody products, and conducted research into T-cell activation and chimeric antigen receptors. He was Director of Molecular Immunology at Coulter Pharmaceutical Inc., Senior Director of Research at Corixa Corp. and led a team that transferred to Medarex Inc on the acquisition by Medarex of antibody-drug conjugate technology and assets from Corixa. In 2003, Dr Bebbington was a co-founder of Celscia Therapeutics, a therapeutic antibody development company which merged in 2004 to form KaloBios Pharmaceuticals Inc. At KaloBios he was Vice President of Research, leading a team that developed a novel antibody humanization technology, “Antibody Humaneering™”, outlicensed to multiple partners, and entered 4 antibodies into clinical trials. He co-founded Allakos in 2012.

He has a Bachelor of Arts in Natural Science from the University of Oxford, U.K. and a Master of Arts and Doctor of Philosophy also from the University of Oxford.

Joined Alta in 2000. She currently serves on the board of directors of Chimerix, Kite Pharma, Portola Pharmaceuticals and Trevena. Farah also led Alta’s investments in Achaogen, Agensys, Cytokinetics, Esperion Therapeutics, Excaliard Pharmaceuticals, Orphan Medical and Renovis. Prior to Alta, Farah was an investment banker at Robertson Stephens & Company between 1987 and 1999, where she focused on biotechnology and other life sciences companies. She was elected a General Partner in 1992 and head of the global life sciences investment banking group in 1995. During that time, she was responsible for building one of the most successful life sciences investment banking franchises on Wall Street. She holds a Master of Business Administration from Stanford University and a Bachelor of Arts in Economics from Smith College.

Has 25 years of life sciences experience and has been involved in the formation and management of numerous biotechnology companies. He is currently Executive Chairman and Chief Executive Officer of Precision Immune, Inc., and was the President, CEO, and Director of Labrys Biologics, Inc. from December 2012 until it was acquired by Teva Pharmaceuticals in July 2014. Prior to joining Labrys, Steve was President, CEO and Director of KAI Pharmaceuticals, Inc. from October 2004 until the company was acquired by Amgen in July 2012. His previous positions have included Senior Vice President of Commercial Operations at Exelixis; Chief Business Officer at Sunesis Pharmaceuticals and VP of Business Development at Isis Pharmaceuticals (now Ionis). He began his career in new product planning at Eli Lilly. He holds a Masters in Management from the Kellogg School of Northwestern University and an undergraduate degree from Brown University. Steve is Chairman of Antiva Biosciences, and a director of Ocera Therapeutics, Chrono Therapeutics, and Cascadian Therapeutics (formerly, Oncothyrean, Inc).

Joined RiverVest in April 2008 as a Venture Partner and became a Managing Director in April 2011. He has over 25 years experience as a successful "drug hunter and developer" in both large and small biopharma, including a decade in small-cap and venture-backed companies. John serves on the board of Otonomy Inc., Lumena Pharmaceuticals, Inc., Allakos and ZS Pharma, all RiverVest Fund II portfolio companies. Prior to joining RiverVest, he was president and CEO of Kalypsys, Inc., and has served on the boards of IDM Pharma, Inc. (acquired by Takeda), Epimmune and Keel Pharmaceuticals, Inc. John holds more than 50 patents and numerous patent applications, primarily in the areas of cancer treatment and inflammatory disease. John worked as a scientist with Searle / Pharmacia, from 1987-2003, including head of discovery research from 1997-2003. Through his efforts, John helped establish the groundwork for new studies that led to the commercialization of several major products, including DayPro, Arthrotec, and most notably, Celebrex, one of the leading pharmaceuticals to treat arthritis. Prior to 1987, John was a senior scientist at E.I. DuPont de Nemours and Company; a member of the Basel Institute for Immunology in Basel, Switzerland; and a research associate in the Department of Microbiology and Immunology at Washington University in St. Louis. Additionally, he has co-authored more than 70 published, peer-reviewed scientific papers. John completed his Ph.D. in immunology from the University of Chicago and his B.S. in biology from Northern Illinois University.

Joined Novo A/S in 2009. He is a member of the Board of Directors of Cardeas Inc, and was a board member of Cytochroma Inc., HemoFocus ApS and Neurokey A/S. In 2004, Peter co-founded Curalogic A/S, served as CEO until 2009 and took the company public in 2006. From 2000 – 2004, he was Chief Operating Officer of 7TM Pharma A/S, which he also co-founded. Previously, he worked for 11 years with NeuroSearch A/S, where he was responsible for pre-clinical and clinical drug development. Peter holds a PhD in medicinal chemistry from the Royal Danish School of Pharmacy. He also held a post-doctoral position with Yale University’s department of organic chemistry.

Has served as an observer on our board of directors since December 2015. Ms. Nuechterlein joined F. Hoffmann-La Roche Ltd. in 2002 and currently serves as a deputy director and head of the Roche Venture Fund. Prior to that, Ms. Nuechterlein served as general counsel for SangStat, Inc. She currently serves on the board of directors for AveXis Inc and Lysosomal Therapeutics Inc and as an observer at Allakos and Epic Sciences. Ms. Nuechterlein holds a B.A. from Valparaiso University and a J.D. from University of Michigan.


Dr Bochner is a co-founder of Allakos.

He received a Bachelor of Arts degree with honors in Natural Sciences from the Johns Hopkins University in Baltimore, Maryland and attended medical school at the University of Illinois College of Medicine in Chicago, where he again graduated with honors. After completing Internal Medicine residency training at the same institution, he began his postdoctoral allergy and immunology training in the laboratory of Dr. Robert Schleimer at Johns Hopkins in the Division of Allergy and Clinical Immunology of the Department of Medicine. In 1988 he joined the faculty at Johns Hopkins. He is board-certified in both internal medicine and allergy and immunology.

In August 2013, Dr. Bochner became the Samuel M. Feinberg Professor of Medicine in the Division of Allergy-Immunology at the Northwestern University Feinberg School of Medicine in Chicago, Illinois. Prior to this, he was Professor of Medicine in the Division of Allergy & Clinical Immunology and a Cosner Scholar in Translational Research at the Johns Hopkins University School of Medicine in Baltimore, Maryland. From 2003-2013 he was the Division Director. He has received several awards including the David M. Levine Excellence in Mentoring Award from the Department of Medicine at Johns Hopkins. Dr. Bochner is a Fellow of the American Academy of Allergy Asthma and Immunology and the American College of Allergy Asthma and Immunology. He is a member of the American Society for Clinical Investigation, the Association of American Physicians, President-Elect of the International Eosinophil Society and Vice President of the Collegium Internationale Allergologicum. He was Associate Editor for the Journal of Allergy and Clinical Immunology from 1993-2013, and remains co-Editor-in-Chief for the Allergy and Immunology Section of the online resource UpToDate and an editor of the Middleton's Allergy: Principles and Practice textbook among others. He previously served on the Board of Directors of the American Board of Allergy and Immunology and the Board of Directors for the American Academy of Allergy Asthma and Immunology. He is currently a member of the Hypersensitivity, Autoimmune, and Immune-mediated [HAI] Diseases Study Section. He is the author of more than 250 peer-reviewed publications, reviews, and book chapters, with an interest in the mechanisms of allergic cell recruitment, activation and survival in human allergic inflammatory responses. He sees patients with a particular interest in eosinophilic disorders, and was the principal investigator for the Johns Hopkins T32 training grant that funds postdoctoral education related to careers in discovery in the fields of allergy and Immunology. His ongoing research work, which is funded by grants from the NIH, focuses on the glycobiology and function of Siglec-8 (which he co-discovered in the late 1990’s) and related inhibitory receptors on cells of the immune system.


Dr Schleimer is a co-founder of Allakos.

He majored in Biology at The University of California, San Diego andreceived a Ph.D. in Pharmacology and Toxicology at UC Davis. Dr. Schleimer received post-doctoral fellowship training at the Johns Hopkins University School of Medicine in the Division of Clinical Immunology. Dr. Schleimer joined the faculty at Johns Hopkins in 1981 and became Professor of Medicine in 1992. Dr. Schleimer moved to Chicago to become the Roy and Elaine Patterson Chair and Chief of the Division of Allergy-Immunology at Northwestern University Feinberg School of Medicine in the spring of 2004. Dr. Schleimer has published over 325 papers and was recognized as one of the most highly cited researchers of the last two decades worldwide by The Institute for Scientific Information (ISI). He has had continuous NIH funding for 30 years and presently has an NIH MERIT award, a T32 training grant, a NIH U19 program project grant on Chronic Rhinosinusitis and is coinvestigator or mentor on other NIH grants. He has served on numerous NIH committees and advisory boards for pharmaceutical companies and biotechnology firms. He is presently actively involved in studying the molecular mechanisms of allergic disease, focusing on inflammation, innate and adaptive immunity, cytokines and chemokines, food allergy, the molecular basis for anti-inflammatory steroid action in allergic diseases and the mechanisms of pathogenesis in Chronic Rhinosinusitis.